Companies Have a Unique Opportunity to Seize the MFN Narrative. Here Are Seven Ways to Do That

Inflection Point If you’re into the IRA, it’s worth carving out a few minutes today to read this white paper from Avalere on the development path of cardiovascular medicines and

I was excited yesterday by the even-handed coverage of the move, by Harrow, to increase the price of an eye treatment from $161 to $944 per unit.  But 46Brooklyn’s Antonio

Sorry for the surprise absence of Cost Curve yesterday. Turns out, there really wasn’t much to say, and I didn’t want to clog your inbox. Speaking of absences, Cost Curve